Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (Nasdaq: DFTX) announced a proposed underwritten public offering of $500 million in common shares and pre-funded warrants. Underwriters may receive a 30-day option to purchase up to $75 million of additional common shares.
Proceeds are intended for R&D, potential DT120 ODT commercialization preparation, and general purposes.
Definium Therapeutics (DFTX) reported positive topline results from the Phase 3 Emerge study of single-dose DT120 ODT 100 µg in adults with major depressive disorder.
The trial met its primary and all key secondary efficacy endpoints, with rapid, durable MADRS improvements and a generally favorable safety profile without serious adverse events or suicidality signal.
Definium Therapeutics (DFTX) plans a live webcast on June 22, 2026, at 8:00 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study of a single 100 µg dose of DT120 ODT in adults with major depressive disorder.
The webcast replay will be available in the Investor Relations section of the company website for at least 30 days.
Definium Therapeutics (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company focused on psychiatric and neurological disorders, granted inducement stock options to six newly hired non-executive employees effective June 15, 2026.
The grants cover 155,480 common shares, have an exercise price equal to the grant-date closing share price, vest over four years, were approved under NASDAQ Rule 5635(c)(4), and were issued outside existing equity incentive plans.
Definium Therapeutics (NASDAQ:DFTX) granted inducement equity awards to thirteen newly hired non-executive employees. The awards comprise options to purchase an aggregate of 462,190 common shares, granted on May 18, 2026 and June 1, 2026, with exercise prices set at each grant date’s closing share price.
The options vest over four years: 25% on the first anniversary, then 75% in equal monthly installments over the next three years, subject to continued employment. According to Definium, the grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) as material inducements to employment and were issued outside existing equity incentive plans.
Definium Therapeutics (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company focused on psychiatric and neurological disorders, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026 at 3:10 p.m. EDT.
Webcast replays will be available for 90 days on the investor relations site.
Definium Therapeutics (Nasdaq: DFTX) has dosed the first patient in Ascend, its second Phase 3 pivotal study of DT120 ODT (lysergide tartrate) for major depressive disorder (MDD). The U.S. trial plans to enroll 175 participants, with topline 12-week double-blind data expected in 2027.
Ascend’s primary endpoint is change from baseline in MADRS score at Week 6 for DT120 ODT 100 µg versus placebo. The two-part design, including a 40-week open-label extension, aligns with Definium’s Emerge MDD study and Phase 3 GAD program.
Definium Therapeutics (NASDAQ:DFTX) granted inducement stock options to five new non-executive employees, covering an aggregate 255,340 common shares. The options were approved April 28, 2026, carry exercise prices equal to the grant-date closing share prices, and were issued under Nasdaq Rule 5635(c)(4) outside existing equity plans.
Vesting occurs over four years: 25% after one year, then monthly vesting over the next three years, subject to continued employment.
Definium Therapeutics (NASDAQ: DFTX) reported Q1 2026 results and program updates on May 7, 2026. Key points: three Phase 3 topline readouts for DT120 ODT are expected within ~five months; Emerge and Voyage enrollment complete; Panorama topline moved to late 3Q 2026; Ascend dosing starting in 2Q 2026.
Cash, cash equivalents and investments were $373.4 million as of March 31, 2026, which the company believes will fund operations into 2028. A company webcast was held at 4:30 p.m. EDT on May 7, 2026.
Definium Therapeutics (NASDAQ: DFTX) will report first-quarter 2026 financial results and discuss recent business highlights during a live webcast on May 7, 2026 at 4:30 p.m. EDT. The webcast covers results for the quarter ended March 31, 2026. A replay will be archived on the company's Investor Relations website for at least 30 days.
Analysts may register to participate in the Q&A; listeners are advised to join 15 minutes early.